Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study

Authors
Category Primary study
JournalInternational forum of allergy & rhinology
Year 2026
Key Points: Self-controlled analysis: mean episodes reduced from 2.72 to 1.18 per year; 56.6% reduction. Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS). Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS).
Epistemonikos ID: fbe72167d907f5d165e57a83c1668efba39e9d20
First added on: Aug 15, 2026